Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. announced a planned leadership change in its finance team. On June 1, 2026, Chief Financial Officer Lisa Locklear informed management she will step down from the CFO role effective July 10, 2026. She plans to pursue board opportunities and other professional and personal interests, and the company states her resignation is not due to any disagreement over operations, policies, or practices.
Longeveron expects its current controller, Marie Washburn, to be elevated into the CFO position following Locklear’s departure, pending finalization of her contract. This indicates an internal succession approach rather than an external search.
Longeveron Inc. is asking stockholders to approve several major corporate actions at a fully virtual annual meeting on July 1, 2026. Proposals include electing three Class II directors, sharply increasing authorized Class A common shares to 175,000,000, and authorizing a reverse stock split between 1:2 and 1:20 to support Nasdaq listing requirements.
The company also seeks to add 5,000,000 shares to its 2021 Incentive Award Plan, bringing the plan total to 10,657,440 shares, and to ratify CBIZ CPAs P.C. as auditor for fiscal 2026. As of the May 11, 2026 record date, there were 30,148,947 Class A and 1,449,005 Class B shares outstanding, with Class B carrying five votes per share.
Longeveron Inc. ownership reported by Janus Henderson Group plc: 1,291,331 shares, representing 5.9% of Class A Common Stock as of 03/31/2026.
The filing states the Asset Managers exercise shared voting and dispositive power over these shares on behalf of multiple managed portfolios and disclaim rights to dividends or sale proceeds tied to those portfolio clients.
Longeveron Inc. reported first quarter 2026 results and outlined a shift to a more capital-efficient, asset-light model focused on partnering its stem cell therapy laromestrocel across four programs. For the quarter ended March 31, 2026, revenue was $398,000, slightly above $381,000 a year earlier, driven mainly by clinical trial revenue.
The company posted a net loss of $4.7 million, modestly improved from a $5.0 million loss in 2025, with operating expenses of $5.0 million. Basic and diluted net loss per share was $0.19 on 24.8 million weighted average shares. Cash and cash equivalents rose to $15.8 million from $4.7 million at December 31, 2025, increasing total assets to $21.2 million.
Longeveron highlighted upcoming catalysts, including top-line Phase 2b results in Hypoplastic Left Heart Syndrome expected in August 2026, and described an active partnering strategy targeting HLHS, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Longeveron Inc. reported March 31, 2026 quarter results showing total revenue of $0.4M and a net loss of $4.7M, slightly improved from a $5.0M loss a year earlier. Cash and cash equivalents rose to $15.8M, helped by an initial private placement that raised roughly $15.9M and warrant exercises.
Total assets increased to $21.2M, with stockholders’ equity expanding to $16.0M. However, the company has an accumulated deficit of $137.0M and expects to continue incurring operating losses as it advances laromestrocel, its lead regenerative medicine candidate, through clinical development.
Management expects existing cash, including private placement proceeds, to fund operations into the fourth quarter of 2026, but its forecast shows insufficient cash to cover minimum commitments for 12 months. As a result, Longeveron discloses substantial doubt about its ability to continue as a going concern and indicates it must secure additional financing or revise its operating plan.
Longeveron Inc. reported outcomes of a recent Type C meeting with the U.S. FDA on its Phase 2b ELPIS II trial of laromestrocel (LOMECEL-B) for hypoplastic left heart syndrome (HLHS). The FDA stated that the trial’s current primary endpoint, right ventricle ejection fraction (RVEF), is not appropriate to demonstrate efficacy and, without an agreed primary endpoint, no longer refers to ELPIS II as a pivotal study.
The FDA highlighted objective measures such as all-cause mortality, cardiac transplant-free survival, cardiac transplantation events and major adverse cardiac events as more informative, and Longeveron is collecting these in ELPIS II. The company plans to submit a Sponsor Statistical Analysis Plan with a composite primary endpoint and secondary endpoints for FDA review, ahead of anticipated top-line ELPIS II results in August 2026 and a potential future Biologics License Application.
Lehr Paul T reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. reported that General Counsel and Secretary Paul T. Lehr received an equity grant of 250,000 shares of Class A common stock as a time-based vesting Restricted Stock Unit (RSU) award. The filing notes that Lehr’s holdings, including RSUs subject to future vesting, total 588,566 shares after this grant.
Willard Stephen H reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. Chief Executive Officer Willard Stephen H received an equity compensation award of 500,000 shares of Class A Common Stock on May 1, 2026. The award is structured as time-based vesting Restricted Stock Units (RSUs) granted at a stated price of $0.00 per share, so it is not an open-market purchase.
Following this grant, his directly held position in Longeveron Class A Common Stock is reported as 789,727 shares, which includes RSUs that are still subject to future vesting conditions.
Longeveron Inc. reported that CTO & SVP of CMC Devin Blass acquired 250,000 shares of Class A Common Stock on a grant/award basis. The shares were awarded as time-based vesting Restricted Stock Units, and total direct holdings increased to 441,543 shares, including RSUs subject to future vesting.